Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174746 · ClinicalTrials.gov registry record · Phase 2
Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,145
- Enrollment target
NCT00174746 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 1,145 participants.
The verdict
NCT00174746, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
To investigate the efficacy and safety of ciclesonide inhaled into the lungs in a range of doses in a new dry powder inhaler compared to ciclesonide inhaled into the lungs using a metered dose inhaler
Interventions
- DRUG AVE2635A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174746
The ClinicalTrials.gov registry entry for NCT00174746 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVE2635A is the first listed.
NCT00174746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174746 about?
NCT00174746 is a clinical study titled "Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma". To investigate the efficacy and safety of ciclesonide inhaled into the lungs in a range of doses in a new dry powder inhaler compared to ciclesonide inhaled into the lungs using a metered dose inhaler
What is the current status of trial NCT00174746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,145 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00174746?
The interventions under investigation include: AVE2635A (DRUG).
Who is sponsoring clinical trial NCT00174746?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.